Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
Focus on Studying, Developing and Commercializing Innovative New Cellular Therapies to Address $5 Billion Wound Care Market Using Company's ADSCs and Patented Cell Culture Mediums
May 14, 2013 08:30 | Source: American CryoStem Corp.
EATONTOWN, N.J., May 14, 2013 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
American CryoStem has teamed with Kathryn Uhrich, PhD, Professor and Dean, Mathematical & Physical Sciences; KiBum Lee, PhD, Assistant Professor of Chemistry & Chemical Biology; and Prabhas Moghe, PhD, Professor and Vice-Chair of Biomedical Engineering and Professor of Chemical and Biochemical Engineering, all of whom will be utilizing the Company's autologous Adipose-Derived Stem Cells (ADSCs) and patented, serum free, GMP grade, cell culture and differentiation mediums to research, develop and commercialize innovative new cellular therapies addressing the $5 billion global wound care market.
"American CryoStem was founded in New Jersey in 2008, completed its initial research and development work in New Jersey, and built its FDA-registered tissue laboratory in the Burlington County College (BCC) High Technology and Life Science Incubators, where we perfected and validated our proprietary and patented technologies," John S. Arnone, CEO of American CryoStem, said. "Rutgers was the next logical step for development and expansion of our cellular therapy products. We are very proud to be collaborating with the State's top bio-tech academic research institution and to be part of the global development of cellular therapies."
The initial stage of collaboration with Rutgers University will provide for Drs. Uhrich, Lee and Moghe to identify, understand and publish their findings on engineered biomaterial interaction with adipose-derived stem cells, the Company's cell culture media and the resulting tissue growth when used in the treatment of chronic or hard-to-heal wounds, such as diabetic and pressure ulcers. American CryoStem developed and patented a new cell culture medium for growing human stromal cells (including all cells found in human skin, fat and other connective tissue) that is animal product free and suitable for human clinical and therapeutic uses. Future stages of collaboration will focus on testing and data collection with a goal of progressing to clinical studies and trials with an end result of the commercialization of effective, new cellular therapy products.
Anthony Dudzinski, COO of American CryoStem, noted, "Rutgers' intellectual resources and extensive research experience in the field of Regenerative Medicine, coupled with our Company's proprietary technologies and expertise with adipose-derived stem cells, provide a powerful combination of skill, knowledge and a common mission – to advance the study, development and commercialization of exciting new stem cell therapies that are capable of effectively treating human illnesses and diseases."
The Rutgers-American CryoStem interactions were conceived by Dr. Kathryn Uhrich, the Dean of the Mathematical and Physical Sciences at the Rutgers School of Arts of Sciences. Dr. Uhrich is widely recognized as one of the leading innovators in polymer research. She is engaged in the study of the synthesis and characterization of biocompatible polymers for medical and dental applications, such as drug delivery and tissue engineering.
Dr. KiBum Lee obtained his PhD in Chemistry from the Northwestern University and completed his postdoctoral research in stem cell biology at the Scripps Research Institute. His primary research interest is in developing and integrating nanotechnologies and chemical functional genomics to modulate signaling pathways in cells (e.g. stem cells and cancer cells) towards specific cell lineages or behaviors.
Dr. Prabhas Moghe is a leading expert in stem cell bioengineering and profiling cell-biomaterial interactions. An International Fellow of Biomaterials Science and Engineering, he has directed a NSF funded IGERT Program on Stem Cell Science and Engineering, the first of its PhD training program in the USA and continues to direct a NIH CORE resource center on polymeric biomaterials on high content imaging technologies to purify and forecast stem cell fates in complex microenvironments. Dr. Moghe's team will investigate and benchmark stromal cell phenotypes in three-dimensional biomaterials.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Hanover|Elite
Kathy Addison or Dodi Handy
407-585-1080 or via email at
American CryoStem and Protein Genomics Form Autogenesis Corporation to Support Development of Unique Stem Cell-Based Wound Products
Author: American CryoStem
Publish Date: Nov 14 2013
Published in Press Releases, Uncategorized
EATONTOWN, N.J. – (GlobeNewsWire) – November 14, 2013 – American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the formation of Autogenesis Corporation (“Autogenesis”) as part of its collaborative agreement to develop wound healing products and other cellular therapies with privately-held Protein Genomics (PGen).
Owned 50
/50 by the Companies, Autogenesis will serve as a dedicated business unit focused on continuing and accelerating the research and development of innovative new products and biotechnologies that combine American CryoStem’s ATcells™ (adipose derived regenerative cells) and ACSelerate™ cell media culture products with PGen’s Elastatropinâhuman-based protein materials.
Dr. Burt Ensley, CEO of Protein Genomics stated, “Elastatropin is created from human protein and, when combined with ATcells, has some unique properties that make it ideally suited for the development of topical cellular products. Based on PGen and American CryoStem’s collective research and development efforts to date, we believe that our work could lead to a significant body of new intellectual property and a whole host of promising new applications in the field of Regenerative Medicine. We are very pleased that our relationship with American CryoStem continues to evolve and strengthen, and are optimistic that the formation of Autogenesis will allow us to support and accelerate the required clinical work necessary to advance new products through the FDA review and approval process.”
Pursuant to the previously announced Memorandum of Understanding entered into by American CryoStem and PGen in September 2012, and having successfully met certain defined clinical milestones, both companies have agreed to form Autogenesis, an entity to which each have licensed their respective technologies. From this point forward, Autogenesis will be responsible for perpetuating research and development of all prospective new products and technologies – and retain ownership of any future intellectual property – which results from the combination of ATcells, ACSelerate and Elastatropin.
“The advancement of our collaboration with PGen is a significant step forward for American CryoStem and represents an exciting value creation event for our shareholders. Autogenesis should serve as an effective, independent vehicle for accessing the funding necessary to support Autogenesis’ next phase of clinical development work and any related collaborations with university and private research facilities that may be beneficial to the project,” noted John Arnone, CEO of American CryoStem.
Continuing, Arnone added, “We expect that Autogenesis will prove to be a strong, replicable business model for our Company with respect to future development projects involving the teaming of our core intellectual property and products with other biotechnology, products, companies and research organizations. Moreover, we believe that this is a highly efficient approach to enhancing shareholder value while widening the scope of opportunities for us to fully optimize our intellectual property, core products and laboratory expertise in a less dilutive manner.”
About Protein Genomics, Inc.
Protein Genomics is led by Dr. Burt Ensley, an Amgen alumni, and former Board member of the National Science Foundation’s BIO Directorate. Dr. Ensley holds 19 issued patents in molecular biology. Protein Genomics produces refined biomaterials using gene synthesis, engineering design and fermentation manufacturing. He is currently on the adjunct faculties of the University of Arizona and Northern Arizona University, and serves as Chairman and CEO of Dermaplus, Inc.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem Corporation is engaged in building a worldwide network of state-of-the-art clinical laboratories dedicated to processing, commercial bio-banking and manufacturing cellular applications using autologous adipose (fat) tissue and Adipose-Derived Regenerative Cells (ADRCs). The Company maintains a strong, strategic portfolio of intellectual property, patent applications and proprietary operating procedural processes that form its Adipose Tissue Processing Platform, which in turn, supports the growing pipeline of biologic products and processes, clinical services and international licensing opportunities. More specifically, this platform enables the cryopreservation of an individual’s adipose tissue which when needed can be further clinically processed into Stromal Vascular Fraction (SVF), which contains ADRCs, other regenerative cells, including white blood cells, endothelial cells, smooth muscle cells, pericytes, fibroblasts and pre-adipocytes, among others. Through its ACS Laboratories division, the Company operates its flagship FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey.
For more information, please visit www.americancryostem.com and www.acslaboratories.com.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Because the info posted here is needs clarification. As rapid advances are being made in this sector, and because stem cell tech is the future of regeneration medicine. ACS operates an FDA approved cGMP cryopreservation lab, and it is the premier stem cell collecting, processing, and storage facility in the US. Their portfolio of intellectual property is growing, and they are forming key collaborative agreements w. prestigious research facilities, and other sector companies.
CRYO is a LTBH, imo.
Disclosure: LONG
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
Focus on Studying, Developing and Commercializing Innovative New Cellular Therapies to Address $5 Billion Wound Care Market Using Company's ADSCs and Patented Cell Culture Mediums
May 14, 2013 08:30 | Source: American CryoStem Corp.
EATONTOWN, N.J., May 14, 2013 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
American CryoStem has teamed with Kathryn Uhrich, PhD, Professor and Dean, Mathematical & Physical Sciences; KiBum Lee, PhD, Assistant Professor of Chemistry & Chemical Biology; and Prabhas Moghe, PhD, Professor and Vice-Chair of Biomedical Engineering and Professor of Chemical and Biochemical Engineering, all of whom will be utilizing the Company's autologous Adipose-Derived Stem Cells (ADSCs) and patented, serum free, GMP grade, cell culture and differentiation mediums to research, develop and commercialize innovative new cellular therapies addressing the $5 billion global wound care market.
"American CryoStem was founded in New Jersey in 2008, completed its initial research and development work in New Jersey, and built its FDA-registered tissue laboratory in the Burlington County College (BCC) High Technology and Life Science Incubators, where we perfected and validated our proprietary and patented technologies," John S. Arnone, CEO of American CryoStem, said. "Rutgers was the next logical step for development and expansion of our cellular therapy products. We are very proud to be collaborating with the State's top bio-tech academic research institution and to be part of the global development of cellular therapies."
The initial stage of collaboration with Rutgers University will provide for Drs. Uhrich, Lee and Moghe to identify, understand and publish their findings on engineered biomaterial interaction with adipose-derived stem cells, the Company's cell culture media and the resulting tissue growth when used in the treatment of chronic or hard-to-heal wounds, such as diabetic and pressure ulcers. American CryoStem developed and patented a new cell culture medium for growing human stromal cells (including all cells found in human skin, fat and other connective tissue) that is animal product free and suitable for human clinical and therapeutic uses. Future stages of collaboration will focus on testing and data collection with a goal of progressing to clinical studies and trials with an end result of the commercialization of effective, new cellular therapy products.
Anthony Dudzinski, COO of American CryoStem, noted, "Rutgers' intellectual resources and extensive research experience in the field of Regenerative Medicine, coupled with our Company's proprietary technologies and expertise with adipose-derived stem cells, provide a powerful combination of skill, knowledge and a common mission – to advance the study, development and commercialization of exciting new stem cell therapies that are capable of effectively treating human illnesses and diseases."
The Rutgers-American CryoStem interactions were conceived by Dr. Kathryn Uhrich, the Dean of the Mathematical and Physical Sciences at the Rutgers School of Arts of Sciences. Dr. Uhrich is widely recognized as one of the leading innovators in polymer research. She is engaged in the study of the synthesis and characterization of biocompatible polymers for medical and dental applications, such as drug delivery and tissue engineering.
Dr. KiBum Lee obtained his PhD in Chemistry from the Northwestern University and completed his postdoctoral research in stem cell biology at the Scripps Research Institute. His primary research interest is in developing and integrating nanotechnologies and chemical functional genomics to modulate signaling pathways in cells (e.g. stem cells and cancer cells) towards specific cell lineages or behaviors.
Dr. Prabhas Moghe is a leading expert in stem cell bioengineering and profiling cell-biomaterial interactions. An International Fellow of Biomaterials Science and Engineering, he has directed a NSF funded IGERT Program on Stem Cell Science and Engineering, the first of its PhD training program in the USA and continues to direct a NIH CORE resource center on polymeric biomaterials on high content imaging technologies to purify and forecast stem cell fates in complex microenvironments. Dr. Moghe's team will investigate and benchmark stromal cell phenotypes in three-dimensional biomaterials.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
Hanover|Elite
Kathy Addison or Dodi Handy
407-585-1080 or via email at
CRYO w. huge upside potential! American Cryostem, emerging leader in stem cell and tissue storage and preservation. Enormous growth potential.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
http://www.americancryostem.com/
Long
CRYO w. huge upside potential! American Cryostem, emerging leader in stem cell and tissue storage and preservation. Enormous growth potential.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
http://www.americancryostem.com/
Long
Deleted post.
CRYO w. huge upside potential! American Cryostem, emerging leader in stem cell and tissue storage and preservation.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
CRYO w. huge upside potential! American Cryostem, emerging leader in stem cell and tissue storage and preservation.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
Amen!! Senate democrats recently voted to reduce the pension benefits of military veterans. In Nov. we need to vote these Senators right onto the unemployment line.
This was fun until dissenting opinions became unwelcome...
Hey, hey, hey... Long time no see...
CRYO American Cryostem emerging leader in stem cell and tissue storage and preservation.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
American Cryostem emerging leader in stem cell and tissue storage and preservation.
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=64906684&topic=CRYO&symbology=null&cp=off&webmasterId=89753
Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
'Type 1 diabetic, cannot get real health insurance, which he has not had for nearly 20 years, at any cost -- and he very strongly objects to your in any way using him or his example as any sort of support for your ravings'
Regs covering pre-existing conditions vary state by state. NJ private insurers are required to provide health coverage, with pre-existing conditions being covered after 1 full year of continuous coverage.
Further, since you find the content of my posts objectionable, and have expressed the same on numerous occasions -- perhaps because my opinions differ from you own(??), I will, again, refrain from posting -- and the group here can continue to cheer team Obama without question or dissent. AND, as with the previous admin, we will certainly get the gov (and the healthcare "reform") we deserve. You can bet on that!
Have a nice day !! :)
And if Bush had made the same moronic, misleading statements, there would be outrage on this thread. No hyperbole whatsoever...
Peg, I can assure you the folks in Jersey Shore's waiting room were not "planted" by anyone. They were people, just like you and I, waiting for a family member to return from the OR. There were at least 15 people, and every single one of them (except me) vocalized anger at what the prez had said.
Re: Diabetes... Every major hospital around here has a diabetes center, and insurance typically pays for more cost effective preventive care. Ultimately, it is up to the patient to comply with treatment protocols. That cannot be forced -- even by the prez.
We have a poster here who has previously stated that s/he is diabetic, but because of competent and probably meticulous self care, the poster has experienced minimal, if any of the typical complications of diabetes. If all diabetics did the same, we would dramatically decrease the overall cost to the system. Unfortunately, that is not the case.
Prevention is being promoted in physicians offices all over this country, as well as thru gov sponsored public health campaigns. Everyone knows "an ounce of prevention is worth a pound of cure" but how does the gov enforce this? The idea of prevention is nothing new, it is the most desirable scenario.
Re: Obama's comments -- The debate is not about over-use of diagnostics. It's about the words that come right from Obama's mouth. For reasons previously stated, his comments are misleading at best, and he will kill any needed reform by his own words.
"May" or "will", that's not the way the system works, and I am not picking apart his statement. Reform for reform's sake is not a good thing -- especially in a matter so serious as this.
I was in a surgicenter waiting room (as pt's family) when the amputation and tonsil comments were played on CNBC. I had to do a double take, there was silence, and one man made a comment about the IRS, and the conversation in the waiting room became visceral. Ergo, when they say "plants" at town hall meetings, they must be "planting" in the Jersey Shore waiting room too.
Obama's hideous statement on tonsils...
"Right now, doctors a lot of times are forced to make decisions based on the fee payment schedule that's out there. So if they're looking and you come in and you've got a bad sore throat or your child has a bad sore throat or has repeated sore throats, the doctor may look at the reimbursement system and say to himself, "You know what? I make a lot more money if I take this kid's tonsils out."
Now, that may be the right thing to do, but I'd rather have that doctor making those decisions just based on whether you really need your kid's tonsils out or whether it might make more sense just to change -- maybe they have allergies. Maybe they have something else that would make a difference."
http://edition.cnn.com/2009/POLITICS/07/22/transcript.obama/index.html
Primary care physicians treating upper respiratory infection and tonsillitis, are not surgeons. Surgeons, ENT's, remove tonsils -- when the clinical situation meets specific, defined criteria. If Obama believes this jibberish, which I find highly unlikely, he is woefully ignorant of the system he is trying to reform...
"All I'm saying is let's take the example of something like diabetes, one of --- a disease that's skyrocketing, partly because of obesity, partly because it's not treated as effectively as it could be. Right now if we paid a family -- if a family care physician works with his or her patient to help them lose weight, modify diet, monitors whether they're taking their medications in a timely fashion, they might get reimbursed a pittance. But if that same diabetic ends up getting their foot amputated, that's $30,000, $40,000, $50,000 -- immediately the surgeon is reimbursed. Well, why not make sure that we're also reimbursing the care that prevents the amputation, right? That will save us money. (Applause.)"
http://www.whitehouse.gov/the_press_office/Remarks-by-the-President-at-Town-Hall-on-Health-Insurance-Reform-in-Portsmouth-New-Hampshire/
As if the medical community is not already providing comprehensive disease education, management and treatment... But we cannot force compliance with any disease mgt program, we cannot for compliance with the ADA food pyramid, or other healthy lifestyle choices. Someone should refer the president to Healthy People 2010, it's all part of a long standing gov public health initiative to improve our overall health status, and end healthcare disparities. Our progress in non-impressive.
If interested, google the president's outrageous comments on tonsillectomies, and the cost of antibiotic therapy for chronic tonsillitis. The Amer College of ENT's has well established criteria defining clinical indications for tonsillectomy.
There is a reason why so many surgical organizations have issued public statements regarding Obama's promotional misinformation.
Poor training, short staffing -- all about no money. And honest human error is always part of the mix...
Obama said doctors get paid 30 or 50 grand for amputation -- indicating a financial incentive for amputation. First of all primary provider who treat diabetes do not do surgery -- so no profit for them. Surgeons do surgery -- and their reimbursement rates have become dismal relative to the risk they take every time they enter the OR. It is likely that the cost to the system is 30 to 50 grand, but NO ONE want to see trauma, surgical or otherwise, inflicted on a diabetic -- for reasons previously stated. Surgery is ALWAY the last resort for these patients, and Obama's comments were misleading at best...
And that situation is, unfortunately, not atypical -- and extremely expensive to treat. Those non-healing wounds often eventually do go septic, and become lifethreatening -- especially in the elderly. I'm assuming you filed a complaint with the facility involved. I'm assuming you did. Further, that type of situation is preventable with the use of scissors specifically designed for the removal of wound dressings with one blunted edge to prevent trauma -- kind of like kindergarden scissors. Likely, your mom's was a preventable event, but I am glad it worked out...
For example -- tonite I was called to assess a diabetic woman's lower extremity skin tears. An 80-something yo woman, happy lady, tight family, with dry, parchment like skin. We will investigate, and certainly this is an unacceptable occurrence, but it is the direct result of limited resources causing insufficient staffing. Meticulous diabetic skin care was needed to prevent this situation -- which will likely turn tragic. The hospital will now do meticulous wound care, with hyperbaric O2 therapy and, still, given the status of her skin, her advanced age, compromised condition, and impaired circulation, she will not heal. So... eventually she will probably go for amputation, or overwhelming infection -- either of which will take a miracle to survive. But this problem is absolutely not greed driven. It is a factor of limited resources in our hospitals today. That's reality -- one (fresh) example.
I did provide links...
I couldn't agree more! Going to the hospital kills alot of people, seriously. We do "root cause" on any error reported -- and staff are required to report. Most of it come right back to the same underlying problem, lack of financial resources, and short staffing. Over the last decade -- shrinking reimbursements, increased losses equals over worked, insufficient staffing and an increase in adverse events. Just the facts... Thus, a reform that does not improve the financial status of hospital is very "bad medicine"...
Medicare only works with a supplement. Otherwise, seniors go broke with the reimbursement structure. And many physicians will not take Medicare without a supplement. The supplement is expensive. Again, Obama will exacerbate the crisis in the hospital infrastructure if he cuts Medicare reimbursement by 5%. Forget about increasing the Medicaid burden to the already broke states. Successful reform has got to shore up the balance sheets of our hospitals. How long can any business operate in the red?
Yeah, the surgeons get a about 11 hundred bucks, rehab is costly, and a functioning titanium prosthetic cost upwards of what a car costs. But, putting the cost in perspective, it's a very functional limb -- with which you can walk, and drive a car, and return to the highest level of function...Further, primary care providers and endocrinologists who treat diabetes don't do artificial limbs, or rhb.
Causing addition tissue trauma to a diabetic is ALWAYS the last resort. Diabetics have delayed wound healing and increased risk for infection, ergo most pose a hugely increased surgical risk, and every effort is made to heal (very common) diabetic foot ulcers. Amputation is ALWAYS the last resort option when necrosis and infection pose a life threatening risk.
OBAMA is his own worst enemy here because, like the last admin, he is playing the public for fools. Some of his statements have been GROSSLY ridiculous, and his plan will fail on his own commentary -- which is unfortunate because some reform is desperately needed.
I agree with everything you say, but believe that Obama has played right into the R-wing, anti-Obama pundits with ignorant statements -- such as the doozie about amputations and tonsils. I honestly take offense at that statement.
You couldn't be more right about the poor quality of hospital care delivery in this country. There is so much bantering about tort reform, yet most people have no idea how many errors they have been subject too, or how many people die just because they were admitted to the hospital. For example, an "industry secret" -- one is subjected to a medication error for every inpatient day of a hospital stay. A med error a day !!
Lots of it is directly related to shoe-string budgets, and short staffing, but that's the reality. Clearly, hospitals have to act more like efficient businesses, and efficiency is a major problem, but ANY reform has got to return solvency to the hospital system. Obama's plan does not do that and will probably create greater financial strain -- by cutting Medicare payments to hospitals by 5%, and passing down a greater share of Medicaid costs to the already cash strapped states.
Bottom line: when bureaucrats do healthcare, they wind up sounding dopey, and we will no doubt get a poor product. They would have been better to draft reform via a panel of healthcare pros from multi disciplines -- administration, finance, pharma, MD, nursing, DME, advocates, social workers, etc... A mulidisciplinary committee...
Peg, You've hit the nail on the head!! The entire campaign re: HC reform is about misinformation -- starting with Obama himself.
I am wondering why a committee of healthcare pros was not commissioned, a group with understanding of all aspects of healthcare delivery, to at least make suggestions regarding reform. Instead, we get bureaucrats all over DC spewing complete jibberish on a topic they clearly know little about...
This is not an R thing or a D thing. It's a DC thing, and they do not know what the heck they're doing with this healthcare bill -- including Obama. For him to say that a physician will lopp off a leg for 30 or 50 grand rather than treat disease is a grotesque falsehood, as well as pure, unadulterate ignorance on so many levels. AND the crowd responds with applause?? Unbelievable.
As always, we get the gov we deserve !!
I am convinced we've put another idiot in the WH...
Doctors hack off limbs and take tonsils for more favorable reimbursement?? Pure, unadulterated ignorance !! And can someone please tell me why DC bureaucrats who know jack about healthcare have taken to "reform" the whole system. Wouldn't that job have been better filled by healthcare professionals from all disciplines -- finance and patient care, etc?
Obama -- we sure can pick 'em !!
The American College of Surgeons is deeply disturbed over the uninformed public comments President Obama continues to make about the high-quality care provided by surgeons in the United States. When the President makes statements that are incorrect or not based in fact, we think he does a disservice to the American people at a time when they want clear, understandable facts about health care reform. We want to set the record straight.Yesterday during a town hall meeting, President Obama got his facts completely wrong. He stated that a surgeon gets paid $50,000 for a leg amputation when, in fact, Medicare pays a surgeon between $740 and $1,140 for a leg amputation. This payment also includes the evaluation of the patient on the day of the operation plus patient follow-up care that is provided for 90 days after the operation. Private insurers pay some variation of the Medicare reimbursement for this service.
Three weeks ago, the President suggested that a surgeon’s decision to remove a child’s tonsils is based on the desire to make a lot of money. That remark was ill-informed and dangerous, and we were dismayed by this characterization of the work surgeons do. Surgeons make decisions about recommending operations based on what’s right for the patient.
We agree with the President that the best thing for patients with diabetes is to manage the disease proactively to avoid the bad consequences that can occur, including blindness, stroke, and amputation. But as is the case for a person who has been treated for cancer and still needs to have a tumor removed, or a person who is in a terrible car crash and needs access to a trauma surgeon, there are times when even a perfectly managed diabetic patient needs a surgeon. The President’s remarks are truly alarming and run the risk of damaging the all-important trust between surgeons and their patients.
We assume that the President made these mistakes unintentionally, but we would urge him to have his facts correct before making another inflammatory and incorrect statement about surgeons and surgical care.
http://www.facs.org/news/obama081209.html
The AMA contacted White House staff last night to again express strong concerns with some recent medical treatment examples used by President Obama. We’ve made it clear that physicians are extremely dedicated and focused—first, foremost and always—on providing care that best serves their patients.
We agree with President Obama on the importance of prevention. However, a recent example used to illustrate his important point was misleading. Surgeons are not paid $30,000 to $50,000 to amputate a diabetic’s foot. Medicare pays a surgeon, on average, from $541.72 to $708.71 for one of two procedures involving a foot amputation. It is possible that the total bill, hospital stay, rehabilitation, prosthesis, etc. may approach the larger amount mentioned.
In the case of tonsillectomies, a patient is referred to a surgeon after medication therapy has proven to be ineffective. Actually, the medical profession itself recognized questions about utilization and appropriateness of tonsillectomies and took action by developing clinical guidelines, which has resulted in a sharp decline in the rate of tonsillectomies.
These types of examples create the impression that physicians are motivated by payment levels rather than what is best for patients. The AMA will continue to stress to our elected leaders that physicians are dedicated to putting patients first and optimizing health care quality.
http://www.ama-assn.org/ama/pub/news/newsletters-journals/health-system-reform-bulletin/hsr-12aug2009.shtml
On the issue of Obama-care...
I cannot even beging to stress the importance of the healthcare decision now facing our elected officials and the US population. While some measure of reform is absolutely needed, Obama-care WILL NOT correct what ails of hospital infrastructure, and that threatens each and every one of us.
In response to the RNC's daily spam mail, I responded as follows, and forwarded the same to our Governor and Senators:
RNC:
I agree that Obama's plan is probably not the "best" plan. In fact, it may exacerbate the problem but, all BS and politicing aside, there is a healthcare crisis in this country, and some effective reform is desperately needed at this time.
The problem is essentially three fold:
1) Because of a grossly disfavorable reimbursement system, and the burden of providing care to the growing uninsured, our hospitals are on fiscal life support. More than half in NJ are insolvent -- running in the red, and many are facing closure. Without an effective, solvent hospital infrastructure, we are a third world country.
2) The States, already in fiscal crisis, cannot afford the escalating costs of providing care to the uninsured.
3) Our current system relies on business to provide health insurance to employees. This cost is escalating at a rate far greater than the rate of inflation, and is an oppressive tax on business, a system that makes US business less able to compete globally. And it is a system that is unsustainable.
Ergo, it is NOT enough to scare the public with the "S" word (socialist!!), and it is not enough to scare seniors -- who happen to vote in disproportionately high percentage. Payor reform is desperately needed NOW. Now, you have been spamming my email daily -- with "Obama is Bad" type rhetoric. This rhetoric ignores a dire problem within our essential hospital infrastructure, it is unproductive, and ridiculous. We need solutions.
In a previous correspondence, I wrote:
Obama and Congress should listen to the governors, bipartisan governors. We are experiencing a fiscal crisis in healthcare, no question, but Obama's plan only exacerbates the existing crisis. By cutting Medicare payments to hospitals by 5% and passing additional Medicaid, and uncompensated care costs onto the states, the plan will dramatically increase the fiscal strain and insolvency of our hospitals. Any effective reform has got to shore up the balance sheets of hospitals with improved profitability. The current plan will absolutely NOT do that.
Without an effective hospital infrastructure, we are a third world country. And when more hospitals close due to insolvency, and more emergency departments close, we can do like Calcutta, and sweep the corpses from the gutters in the morning. No business can operate in the red forever, and our system is in dire need of some reform,
but the current plan will only worsen the crisis by
further financially weakening the existing hospital infrastructure.
So, please, no more bumper sticker type anti-Hillary-care/Obama-care talking points. The country NEEDS and deserves better. Further, I have responded to your daily spam without response. If you choose not to respond to this very serious issue, please remove my name from your email list.
Sincerely,
NJ Registered Republican
I submitted a request, but if I don't hear anything, I'll let you know. Thanks for your help!
I'm not familiar, but will check out the site first thing in the a.m...
I like it too !! :)
Thanks, mick, I will follow up in the morning.
EXOU: How do we do charts system? I'm not familiar with that, but if you explain, I'll see what I can do... TIA! :)